Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
ATryn market authorization transferred to Leo Pharma
January 29th, 2007
GTC Biotherapeutics, Inc., announced that the market authorization of ATryn for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency has been transferred to its distribution and development partner, Leo Pharma A/S, following approval by the European Commission. ATryn is a recombinant form of human antithrombin. Antithrombin is normally found in human plasma and has both anticoagulant and anti-inflammatory properties. The approval of the transfer of the market authorization enables Leo to enter into negotiation of reimbursement rates as part of preparing for the commercial launch of ATryn in Europe on a...
Source: Biotech Business Week (2007-01-29)
|
